Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- Telehealth’s evolution continues as COVID-19 restrictions loosen Rebecca L. Forand
-
- Many Americans will forgo flu shot despite fears of COVID-19 ‘twindemic’ Caitlyn Stulpin
- Joel M. Gelfand, MD, MSCE, named Chief Medical Editor of Healio Psoriatic Disease
- FDA approves Simponi Aria for polyarticular JIA, expands PsA indication to children Robert Stott
- FDA, EMA accept bimekizumab applications for plaque psoriasis
- Q&A: Social Media Affects Psoriasis Education, Acceptance Rebecca L. Forand
- COVID-19 outcomes worse in patients with inflammatory arthritis receiving glucocorticoids Jason Laday
- Psoriatic microenvironment may help predict treatment response Rebecca L. Forand
- Calcipotriene/betamethasone dipropionate foam shows long-term efficacy in plaque psoriasis Rebecca L. Forand
-
- Ustekinumab may trigger severe cardiovascular events in high-risk individuals Rob Volansky
- Combination therapy, personalized medicine on the horizon in psoriatic arthritis Stacey L. Adams
- Dermatologist: Keep these three topical steroids 'in your back pocket' Jason Laday
- Gout-PsA overlap warrants new look at disease mechanisms, role of urate crystals Robert Stott
- Clinicians treating PsA may no longer be 'throwing a dart' to choose optimal drug Rob Volansky
- Most physicians prescribe antifungals for inverse psoriasis Rebecca L. Forand
- Psoriasis negatively affects QOL for patients, family members Rebecca L. Forand
- Latent TB infection uncommon after secukinumab treatment Kate Burba
-
- Biologic therapy for severe psoriasis may also reduce coronary artery plaque Scott Buzby